Shares of NeoGenomics plunged 11% to $17.02 on October 6, erasing weeks of gains even as broader markets traded higher. The catalyst: a mixed bag delivered after the close on October 5 that paired a solid preliminary revenue beat with a CEO departure and no upgrade to full-year targets — a combination investors clearly read as more risk than reward. NeoGenomics Posts a Revenue Beat but Investors Flee — Will a New CEO and Deferred Guidance Stall a Turnaround in Progress?

Shares of NeoGenomics cratered 11% to $17.02 on October 6 while the broader market rose, after a Sunday-evening announcement bundled a promising revenue preview with an unwelcome leadership shake-up and a puzzling refusal to formally lift targets. Investors got three signals at once — and two of them raised questions.

A Revenue Beat Without the Formal Upgrade Investors Wanted

The company reported preliminary Q3 revenue of roughly $209 million, with next-generation sequencing (advanced DNA-based cancer tests) growing about 28% year-over-year. That tops analyst expectations of approximately $205.9 million and marks a clear acceleration from Q3 guidance of "about 10%" revenue growth issued in July. But here's the rub: NeoGenomics reiterated its full-year revenue and adjusted EBITDA guidance, saying only that it expects to raise the midpoint on the upcoming earnings call.

Current full-year revenue guidance sits at $802–$806 million. A $209 million Q3 implies the company is running well ahead of that pace, yet management chose to defer any official raise — leaving shareholders with a promise, not a commitment.

A CEO Change Adds Uncertainty at a Pivotal Moment

Warren Stone, currently President and COO, will succeed Tony Zook as CEO effective January 4, 2027 , while Zook will become Executive Chairman.

Stone, 54, has over three decades of diagnostics experience and has held roles of increasing responsibility since joining in 2022. The company framed this as "strategic continuity," but CEO transitions at still-unprofitable companies spook the market. NeoGenomics remains cash-flow negative , making execution under new leadership a genuine risk.

The Growth Trajectory Is Real — but So Is the Profitability Gap

Q2 revenue was $201.7 million, up 11% year-over-year, with adjusted EBITDA growing 36%.

For the full year, the company still guides toward a net loss of $34–$42 million. NGS growth of 28% in Q3 — up from 26% the prior two quarters — shows accelerating demand for precision oncology testing. But until losses narrow more visibly, the stock trades on sentiment, not fundamentals.

What to Watch on October 27

NeoGenomics reports full Q3 results on October 27 before the market opens. That call will determine whether the deferred guidance raise, paired with a concrete profitability trajectory under incoming CEO Stone, can restore investor confidence — or whether today's 11% haircut becomes the new baseline.